[Use of Reamberin for the prevention of adverse effects of combined antineoplastic agents in stage III-IV ovarian cancer during induction treatment].
Ovary cancer treatment often presents clinical promlems due to frequent occurence of late diagnostics (III-IV stages), severe treatment complications in patients with ascitis and tumor intoxication. Reamberin can be used as supportive therapy aimed at decrease of intoxication, which is one of the main hindrances for antitumor therapy. In the current study reamberin was used in 89 stage III-IV (FIGO) ovary cancer patients with ascitis, age 42 to 79, CP or CAP chemotherapy recipients after prior cytoreductive surgery. The occurrence of hematological complications (grade 1-2 anemia and neutropenia) and cardiac dysfunctions in the study group was much lower, than in the control group. This difference is statistically valid (p < 0.01 and p < 0.05). The patients receiving reamberin prior to chemotherapy or during chemotherapy rarely (in 3.7% of cases) displayed raised creatinine values. In the control group grade 1-3 renal impairment was observed in 41.4% cases, in 12 cases the therapy had to be ceased. This difference between the groups is statistically valid (p < 0.001). Patients receiving reamberin displayed more rapid rate of CA-125 tumor marker serum concentration decrease. Therefore, reamberin is an effective drug for prevention of chemotherapy side effects and alleviation of intoxication allowing the more rigid chemotherapy schedule without an increase in toxicity.
V G
VG
Cherenkov
A B
AB
Petrov
A A
AA
Shpenkova
T M
TM
Vasil'eva
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008536:Meglumine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011322:Primary Prevention / Q000379:methods*; D020011:Protective Agents / Q000627:therapeutic use*; D012074:Remission Induction; D013386:Succinates / Q000627:therapeutic use*
D020011:Protective Agents; C549374:Reamberin; D013386:Succinates; D008536:Meglumine